Division of Hematology and Oncology

Mary Philip, MD, PhD, left, and Michael Rudloff, PhD, found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. (photo by Anthony Czelusniak)
August 3, 2023

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

By Leigh MacMillan
May 11, 2023

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

By Tom Wilemon
April 18, 2023

Vanderbilt mourns loss of former Hematology leader Krantz

Sanford Krantz, MD, internationally recognized authority on hematology and erythropoietin and professor of Medicine, Emeritus, died April 13 at his home. He was 89.

By VUMC News and Communications
Jordan Berlin, MD, was recognized for his leadership serving on an NCI team that researched and recommended changes to clinical trial protocols that expanded the role of advanced practice providers.
April 6, 2023

National Cancer Institute honors Berlin’s contributions, leadership

Vanderbilt’s Jordan Berlin, MD, is a 2022 recipient of the National Cancer Institute Director’s Award.

By Tom Wilemon
March 30, 2023

New treatment helps mitigate hair loss for chemotherapy patients

Vanderbilt-Ingram Cancer Center has started offering scalp cooling, which mitigates hair loss for patients receiving certain chemotherapy regimens.

By Tom Wilemon
Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

By Leigh MacMillan
February 16, 2023

Targeted therapy for neuroendocrine tumors

Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.
By Kelsey Pinckard
February 6, 2023

Berlin named director of Division of Hematology and Oncology

Jordan Berlin, MD, has been named director of Vanderbilt’s Division of Hematology and Oncology.
By Tom Wilemon
September 29, 2022

New Clinician Spotlight: Muhamed Baljević

Specializing in myeloma, amyloidosis and other plasma cell disorders, hematologist and medical oncologist Muhamed Baljević, MD, recently joined Vanderbilt University Medical Center.
By VUMC News and Communications
September 29, 2022

Policy, resources crucial for lung cancer screening: study

Vanderbilt reseach shows that resources for lung cancer screening programs increased the number of veterans screened.
By Leigh MacMillan
August 29, 2022

Blood cancer progression

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
By Leigh MacMillan
August 11, 2022

Cell-free breast cancer “biopsy”

The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.
By Sarah E. Glass
August 2, 2022

Targeted cancer drug during pregnancy

The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
By Leigh MacMillan